NEO · NeoGenomics, Inc.

Current Thesis

NeoGenomics’ advanced-testing turnaround now has price confirmation; the next quarterly report must sustain July’s raised outlook before a weekly close below $18.64 breaks the extension. The 2026-09-18 adjusted close of $19.91 exceeded the August coverage-associated high of $18.64 documented on 2026-09-05, reversing the earlier failed-breakout reading. The operating foundation remains the 2026-07-28 report: next-generation sequencing (NGS) revenue grew 26% year over year, and management raised full-year revenue guidance to $802–806 million. Q2 results.

As an inference, the narrative is maturing — the July earnings improvement and 2026-08-26 Medicare coverage expansion remain the operating evidence behind the September high. The company’s news index, checked on 2026-09-19, lists its 2026-09-01 conference announcement as the latest release; the price advance therefore cannot yet be attributed to a newly reported operating improvement. Company news.

Bullish and bearish views on NeoGenomics, Inc.

The model's bull view on NeoGenomics, Inc. (NEO), in brief: Advanced testing supports the turnaround. The bear view: Revenue growth exceeded volume growth. The 2026-07-28 earnings materials recorded Q2 average revenue per test of $515, up 11.7% year over year, while clinical volume grew 1.9%. This supports an inference of dependence on pricing and test mix; falling revenue per test in Q3 would… Both cases follow in full.

Bull Case

• Advanced testing supports the turnaround. The 2026-07-28 report showed clinical revenue of $187 million, up 14% year over year, alongside NGS growth of 26%. These measured results support the mix-shift interpretation. Q2 results.
• Reimbursement coverage has widened. NeoGenomics’ 2026-08-26 announcement added Medicare coverage for RaDaR ST molecular residual disease (MRD) testing in immunotherapy response monitoring for late-stage solid tumours. It was the third covered indication; two additional submissions remained pending on that date. Coverage is established evidence; incremental revenue from that expansion has not been supplied.
• Price has recovered the August high. The adjusted daily series records a $19.91 close on 2026-09-18, also its 52-week high, compared with the $17.38 close on 2026-09-04. The earlier observation that the coverage-related advance had failed to hold no longer describes the latest close.

Bear Case

• Revenue growth exceeded volume growth. The 2026-07-28 earnings materials recorded Q2 average revenue per test of $515, up 11.7% year over year, while clinical volume grew 1.9%. This supports an inference of dependence on pricing and test mix; falling revenue per test in Q3 would challenge its durability.
• Reported profit included debt accounting. Q2 2026 net income of $2 million included an $11 million gain on extinguishment of debt. The 2026-07-28 release still projected a full-year net loss of $34–42 million under generally accepted accounting principles (GAAP), limiting the evidence for recurring profitability. Filed earnings release.
• The advance precedes another operating check. The shares’ three-month price increase was 77.8% on 2026-09-18. As checked on 2026-09-19, the company’s investor calendar showed no upcoming events, leaving the next earnings date unconfirmed. Investor calendar.

Setup & Price Structure

The 2026-09-18 adjusted close of $19.91 is the reference close. The August high of $18.64, recorded in the 2026-09-05 coverage, is the observable boundary for this breakout thesis; its role as support remains an inference until tested. A weekly close below $18.64 would invalidate that interpretation.

The 14-day relative strength index (RSI) measured 73.2 on 2026-09-18. Together with the 77.8% three-month advance, it describes strong recent momentum, but does not establish crowded ownership. Current fund flows, short interest, retail participation and moving-average distances are missing; neither a squeeze nor expanding participation is supported by the available evidence.

Catalyst Calendar (next 30 days)

• 2026-09-21 — General counsel transition. The 2026-08-11 filing states that Alicia Olivo ceases serving as general counsel on this date. This is a governance milestone, with no quantified operating effect disclosed. Company filing.
• 2026-10-02 — Scheduled company departure. The same 2026-08-11 disclosure schedules Olivo’s departure from the company. Neither this date nor the legal-role transition resolves the testing-growth thesis.

The 2026-09-15 Morgan Stanley conference is past. As of the 2026-09-19 calendar check, no earnings date or reimbursement decision date was announced for the next 30 days. The next quarterly report remains the operating test; an estimated date is not presented as a scheduled catalyst. Investor calendar.

What Would Change Our Mind

Failure to retain the August breakout would end the price-confirmed turnaround case: a weekly close below $18.64 is the published invalidation condition. That level comes from the August market high documented on 2026-09-05, rather than an inferred moving average.

For this forecast, confirmation means the Q3 report maintains or raises the 2026-07-28 full-year revenue outlook of $802–806 million and retains at least the mid-20s NGS growth outlook before the price condition fires. A reduction in either outlook would reject the operating premise even if the market remained above the price threshold. Conviction is moderate because July’s operating improvement and September’s breakout are measured, while revenue conversion from August’s expanded coverage remains unreported.

Correlation Notes

This is a single-company setup. The 2026-07-28 NGS results and 2026-08-26 RaDaR ST coverage decision identify company-specific drivers, but the supplied evidence contains no matched peer-return series. A correlation with diagnostics equities, biotechnology shares or broader healthcare cannot be quantified, and the limited observations do not establish that a group move caused the 2026-09-18 high.